GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » 3-Year EBITDA Growth Rate

SERA (Sera Prognostics) 3-Year EBITDA Growth Rate : 3.80% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics 3-Year EBITDA Growth Rate?

Sera Prognostics's EBITDA per Share for the three months ended in Mar. 2025 was $-0.19.

During the past 3 years, the average EBITDA Per Share Growth Rate was 3.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sera Prognostics was 3.80% per year. The lowest was -21.00% per year. And the median was -6.20% per year.

Competitive Comparison of Sera Prognostics's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Sera Prognostics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sera Prognostics's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's 3-Year EBITDA Growth Rate falls into.


;
;

Sera Prognostics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sera Prognostics  (NAS:SERA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sera Prognostics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sera Prognostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
RPID CVRX LNSR AVR BDMD RCEL ARAY OWLT LUCD ELMD ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Website
https://www.seraprognostics.com
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Executives
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Mansoor Raza Mirza director C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Douglas Fisher officer: Chief Business Officer 587 PATROL RD, WOODSIDE CA 94062
Gregory C Critchfield director, officer: Chief Executive Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Blue Ox Healthcare Partners Sp, Llc 10 percent owner 135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Ii, Llc 10 percent owner 135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022